Imugene Ltd (ASX:IMU, OTC:IUGNF) will have its CF33 Oncolytic Virus technology featured at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC).
The event will be held in San Diego, USA between November 1-5 2023 and is one of the most prestigious immunotherapy events on the calendar.
SITC 2023 promises to be a hotbed of innovation and collaboration within the oncology community. The event is set to showcase cutting-edge research presentations led by a multitude of experts, supplemented by oral and poster abstract presentations. These sessions will offer myriad opportunities for networking and in-depth discussion.
Among the highlights of SITC 2023 is the acceptance of the CF33 technology for a Trial-in-Progress Poster titled 'A Phase I Safety and Tolerability Study of VAXINIA (CF33-hNIS), a Novel Chimeric Oncolytic Poxvirus, Administered Intratumorally or Intravenously in Adults with Metastatic or Advanced Solid Tumors'.
Abstract number 730.
Imugene will unveil further details from this abstract as the event draws nearer.
SITC 2023 looks to be a vital forum for those seeking the latest developments in oncology. More information about this gathering can be found on the event's official website: https://www.sitcancer.org/2023/home